Genmab A/S stocks have been trading up by 28.9 percent amid strong sentiment around its latest oncology pipeline developments.
Key Takeaways For GMAB Traders
- Positive Phase 3 data for Rina-S in platinum-resistant ovarian cancer showed big reductions in progression or death versus chemo, with no new safety concerns and global regulatory talks planned.
- JPMorgan upgraded Genmab (GMAB) to Overweight, sharply lifting its price target and now modeling $5B in peak sales for petosemtamab on top of Rina-S momentum.
- Combination data for petosemtamab plus pembrolizumab in head and neck cancer delivered 28.2‑month median overall survival and a 63% response rate, backing an ongoing Phase 3 trial.
- In metastatic colorectal cancer, petosemtamab posted 75% first‑line and 67% second‑line response rates, reinforcing GMAB’s late‑stage solid tumor story.
- Bank of America and TD Cowen both raised price targets on Genmab shares while maintaining Buy ratings, pointing to strong new data and bullish sentiment.
Live Update At 12:32:40 EDT: On Wednesday, October 28, 2026 Genmab A/S stock [NASDAQ: GMAB] is trending up by 28.9%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
GMAB has turned from slow grind to momentum rocket in a matter of days. On the daily chart, Genmab A/S went from a close near $38.48 on 2026/10/05 to $57.53 on 2026/10/28. That is a sharp multi‑week trend higher, with the latest move driven by the Rina‑S Phase 3 win. The gap from the 10/27 close at $44.67 to today’s open at $44.63 and run to a $58.54 high shows a classic catalyst breakout.
Intraday, GMAB traded like a textbook high‑volume runner. The stock ripped from the low $50s at the open through the mid‑50s by late morning, then consolidated in the high‑50s with higher lows on 5‑minute candles. That tells traders dip buyers are active, not just day‑trade flippers.
More Breaking News
- Vertiv Holdings Jumps 17% Premarket After Earnings Beat
- WEN Stock Sits Below Targets As Traders Eye Q3 Earnings
- RKT Stock Holds Range As Housing Headwinds Meet Fintech Moves
- OneSpaWorld Jumps 11% After Earnings Beat
Fundamentally, Genmab A/S is priced like a high‑growth biotech. GMAB shows a rich P/E near 155 and a price‑to‑sales ratio over 40, backed by roughly $21.5B in revenue and strong pretax margins above 55%. Return on equity of 6.9% and a leverageratio of 2.2 suggest the balance sheet can support continued R&D. For active traders, this is a story stock: valuation is all about pipeline execution, not current earnings.
Why Traders Are Watching GMAB Right Now
The core driver of this GMAB surge is the RAINFOL‑02 readout. Genmab A/S reported that its antibody‑drug conjugate rinatabart sesutecan (Rina‑S) beat standard chemotherapy in platinum‑resistant ovarian cancer on both progression‑free survival and overall survival, with large risk reductions and no new safety issues. For traders, that means the biggest binary event on this asset just broke positive and dramatically de‑risked the story.
The tape confirmed it. After the data, GMAB popped about $4 to $41.61, and follow‑through buying has now pushed the stock into the high‑50s. This is what momentum traders look for: clean news, clear market reaction, and a chart that holds gains instead of fading.
But Rina‑S is only part of why Genmab A/S is in focus. The bispecific antibody petosemtamab is emerging as a second anchor. In head and neck cancer, GMAB reported updated Phase 2 data with a 28.2‑month median overall survival, 63% overall response rate, and a 19% complete response rate when combined with pembrolizumab. More than half of responders were still in response at 24 months. That durability matters; it tells traders this isn’t just a flashy early signal.
In metastatic colorectal cancer, GMAB showed petosemtamab response rates of 75% in first‑line and 67% in second‑line disease, with 81% in first‑line left‑sided tumors. Those are strong numbers supporting global Phase 3 programs. On top of that, Genmab A/S struck a collaboration with Incyte to test petosemtamab with a KRAS G12D inhibitor and chemo in KRAS‑mutated colorectal cancer, extending the drug’s potential reach with shared costs. Wall Street is reacting: JPMorgan upgraded GMAB to Overweight and now sees $5B in peak petosemtamab sales, while Bank of America and TD Cowen both raised price targets and reiterated Buy ratings.
Conclusion
For active traders, GMAB now checks multiple boxes: fresh Phase 3 win, stacked Phase 2 data, analyst upgrades, and a chart in full breakout mode. Rina‑S looks like a potential new standard in a high‑unmet‑need ovarian cancer setting, and Genmab A/S is already lining up global regulatory discussions. That gives GMAB a clear near‑ to medium‑term catalyst path around filings, label discussions, and future data updates.
At the same time, petosemtamab gives Genmab A/S a second leg of the story across head and neck and colorectal cancers, with combo work in KRAS‑mutated disease adding even more upside. That pipeline depth is what justifies GMAB’s premium valuation for many on the Street, and why the stock has reacted so strongly.
Traders still need to respect risk. Biotech names like GMAB move hard in both directions, and any negative update, delay, or softer‑than‑expected regulatory feedback can flip the script fast. As Tim Sykes likes to say, “patterns repeat, but you have to manage risk because no play is guaranteed.” As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” For those studying GMAB, the key now is to track how the price behaves around support levels, watch volume on every Rina‑S and petosemtamab headline, and remember this is educational and research content only, not a signal to buy or sell.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.